Latest batch of EMA’s human medicines committee recommendations

The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting.

The CHMP recommended granting a marketing authorization for US pharma major AbbVie (NYSE: ABBV) Elahere (mirvetuximab soravtansine), a medicine intended for the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The committee recommended granting a marketing authorization for Hetronifly (serplulimab), from Henlius Europe, for the treatment of extensive-stage small cell lung cancer. By blocking the binding of PD-1 to PD-L1 and PD-L2, serplulimab potentiates T-cell responses, including anti-tumour responses.